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Abstract
Following castration, the transgenic adenocarcinoma
of mouse prostate (TRAMP) model demonstrates rapid
development of SV40-Tag–driven poorly differentiated
tumors that express neuroendocrine cell markers. The
cell population dynamics within the prostates of cas-
trated TRAMP mice were characterized by analyzing
the incorporation of 5-bromodeoxyuridine (BrdUrd) and
the expression of SV40-Tag, synaptophysin, and an-
drogen receptor (AR). Fourteen days postcastration,
the remaining epithelial cells and adenocarcinoma cells
were nonproliferative and lacked detectable SV40-Tag
or synaptophysin expression. In contrast, morpholog-
ically distinct intraglandular foci were identified which
expressed SV40-Tag, synaptophysin, and Ki67, but that
lacked AR expression. These proliferative SV40-Tag
and synaptophysin-expressing intraglandular foci were
associated with the rare BrdUrd-retaining cells. These
foci expanded rapidly in the postcastration prostate
environment, in contrast to the AR– and SV40-Tag–
expressing adenocarcinoma cells that lost SV40-Tag
expression and underwent apoptosis after castration.
Intraglandular foci of synaptophysin-expressing cells
were also observed in the prostates of intact TRAMP
mice at a comparable frequency; however, they did not
progress to rapidly expanding tumors until much later
in the life of the mice. This suggests that the foci of
neuroendocrine-like cells that express SV40-Tag and
synaptophysin, but lack AR, arise independent of
androgen-deprivation and represent the source of the
poorly differentiated tumors that are the lethal pheno-
type in the TRAMP model.
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Introduction
The essentially inevitable recurrence of prostate cancer
(castration-recurrent prostate cancer) that follows androgen-
deprivation therapy (castration) suggests that the prostatic re-
sponse to castration may prime a component of the tumor for
progression to castration-recurrent disease. One possibility is
that androgen-insensitive neuroendocrine (NE) cells signal
through the release of growth and survival factors to the pros-
tate tumor stem cell that also survives androgen-deprivation
therapy, promoting a stem cell– fed emergence of castration-
recurrent disease. NE cells are observed in 50% to 100% of
primary prostate cancers and metastases, and the number of
NE cells correlates with stage, Gleason Grade, and survival
in castration-recurrent prostate cancer [1–3]. However, the
origin of tumor-associated NE cells in castration-recurrent
prostate cancer is unclear. Two potential sources of the NE
compartment in castration-recurrent prostate cancer are: 1)
progeny of prostate tumor stem cells that undergo terminal
NE differentiation in the androgen-deprived environment; or 2)
transdifferentiation of adenocarcinoma cells into NE-like cells.
In the transgenic adenocarcinoma of the mouse prostate
(TRAMP) model, the 426/+28 minimal rat probasin promoter
(rPB) provides androgen-regulated expression of SV40-Tag in
the epithelium of the mouse prostate. The TRAMP transgene
in a C57BL/6  FVB background causes the appearance of
androgen receptor (AR)–expressing adenocarcinomas in the
majority of prostate glands by 16 weeks of age. However, the
poorly differentiated tumors that ultimately kill TRAMP, and 9/
23 (39%) lymph node metastases, but the primary tumors,
expressed synaptophysin [4,5], a widely used marker of NE
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differentiation in mouse and human prostate and CaP [3,6,7].
Furthermore, many of the SV40-Tag–based genetically en-
gineered mouse (GEM) models of prostate cancer also
develop rapidly progressing, poorly differentiated tumors that
express synaptophysin and other NE cell markers [8]. In
TRAMP, castration accelerated (or synchronized) the inde-
pendent emergence of highly proliferative, poorly differenti-
ated tumors that expressed synaptophysin, but had low or
undetectable levels of AR: these tumors, not the more pre-
valent adenocarcinomas, ultimately killed the host [9]. Poorly
differentiated primary or metastatic tumors were found in
up to 93% of 24-week-old TRAMP mice in the C57BL/6 
FVB background that had been castrated at 12 weeks of age
[5,10], whereas 100% of intact TRAMP at 38 weeks of age
mice displayed poorly differentiated tumors [11]. Following
castration at 15 weeks of age, there was only 50% survival at
27 weeks of age, with no survival at 30.5 weeks of age,
whereas 60% of 27-week-old and 30% of 30.5-week-old
intact TRAMP mice in the C57BL/6  FVB background sur-
vived [9]. Castration, therefore, functionally synchronizes
mortality in a subset of TRAMP mice by accelerating or by
facilitating emergence of the poorly differentiated tumors.
The well-differentiated adenocarcinomas present in intact
TRAMP mice responded to castration with cessation of pro-
liferation, induction of apoptosis, and loss of AR-mediated
transactivation, including loss of expression of SV40-Tag. In
contrast, the poorly differentiated tumors within the prostate,
or at sites of metastases, demonstrated no changes in pro-
liferative or apoptotic indices, and maintained expression of
SV40-Tag at 3 days postcastration, the only postcastration
time point examined before the development of palpable tu-
mors in TRAMP mice in the C57BL/6 background [12]. Well-
differentiated adenocarcinomas and poorly differentiated
tumors differ markedly in expressed signaling molecules, in
the expression of markers of differentiation, rates of prolifer-
ation and apoptosis, vessel density, and in androgen respon-
siveness [5,12–17]. With the exception of the study performed
by Wikstrom et al. [12], the response of poorly differentiated
tumors in TRAMP to androgen-deprivation has been analyzed
only in the context of large poorly differentiated tumors [5,9,10],
precluding elucidation of the origin of the these tumors.
Several in vitro and in vivomodels support the hypothesis
of a bidirectional transdifferentiation of prostate cancer cells
into NE cells, particularly in response to androgen-deprivation
[18–20]. Treatment of LNCaP cells with reagents that raise
intracellular levels of cAMP, or enzyme inhibitors that block
degradation of cAMP, or by removal of steroids from the cul-
ture media induced LNCaP cells to assume a neuronal mor-
phology; produce more chromogranin A; secrete bombesin-,
serotonin-, and neuron-specific enolase; and cease expres-
sion of AR and secretion of prostate-specific antigen (PSA)
[18,21–24]. Castration of mice bearing the LNCaP tumor re-
sulted in a 15-fold increase in the number of NE cells within
4 weeks [21]. Finally, the PC-295 and PC-310 human pros-
tate cancer xenografts underwent extensive neuroendocrine
differentiation (up to 50% of the prostate cancer cells) in re-
sponse to castration of the mouse host in the apparent ab-
sence of cellular proliferation [25–27].
Tracking label retention following long-term pulse – chase
labeling with 5-bromodeoxyuridine (BrdUrd) can determine
the origin of NE cells by lineage tracing of the differentiated
progeny of progenitor cells, and/or by demonstration of the
transdifferentiation of mature epithelial cells into NE cells.
Infrequently, proliferating progenitor/stem cells have been
identified as label-retaining cells in many organs, including
the proximal region of the mouse ventral prostate [28], using
BrdUrd retention to identify cells that replicate during the
BrdUrd pulse period and remain quiescent for extended in-
tervals during the chase. Whereas quiescent progenitor/
stem cell retain BrdUrd label, the highly proliferative progeny
of the stem cell/tumor stem cell (the transit-amplifying com-
partment) rapidly dilutes the incorporated BrdUrd with suc-
cessive cell divisions to a level below detection [28]. In fact,
BrdUrd retention was used to demonstrate that transdiffer-
entiation of adenocarcinoma cells to NE cells in the absence
of proliferation was responsible for neuroendocrine differen-
tiation elicited in response to castration in the PC-295 human
prostate cancer xenograft [26]. NE cells in benign prostate
are believed to derive from the prostate epithelial stem cell,
not the neural crest [29,30]. However, in prostate cancer, the
origin of NE cells is unclear. In CaP, NE cells have been ob-
served to coexpress a-methylacyl-CoA racemase (AMACR),
a tumor cell marker, and chromogranin A [31], a neuroendo-
crine marker, suggesting that either AMACR-expressing
prostate tumor cells can acquire the ability to express NE
markers through transdifferentiation or NE cells within areas
of prostate cancer can express AMACR. Because increased
levels of NE differentiation is a characteristic of castration-
recurrent CaP, identification of the mechanism responsible
for the appearance of the NE cells in response to androgen-
deprivation could provide important insights into the biology
of the lethal form of the disease.
This study was initiated to identify the origin and role of
the NE marker–expressing cells in poorly differentiated can-
cers in TRAMP and to determine if the TRAMP model can
enhance our understanding of the origin and contributions
of the NE compartment to the pathogenesis of castration-
recurrent human prostate cancer. This study suggests that NE
marker–expressing cells in the poorly differentiated TRAMP
tumors emerge independent from the adenocarcinomas and
derive from malignantly transformed progenitor cells rather
than from transdifferentiation of adenocarcinoma cells.
Materials and Methods
TRAMP Model
All experiments using laboratory animals were performed
in accordance with the Institutional Animal Care and Use
Committee and the National Institutes of Health guidelines.
Male TRAMP mice [C57BL/6 TRAMP  FVB] F1+/ were
obtained from the colony maintained in the laboratory of
Norman Greenberg at the Baylor College of Medicine and a
colony at Taconic Laboratories. Mice were bred and geno-
typically screened as described [5,9].
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Fourteen-week-old TRAMP mice in the C57BL/6  FVB
background were either castrated by radical orchiectomy or
sham-castrated through a scrotal incision, with a single su-
ture used to close the incision (10 animals/time point). The
dorsal, lateral, and ventral lobes of the prostate, pelvic lymph
nodes, small intestine, and any grossly apparent metastases
were harvested at 0, 1, 2, 4, 7, and 14 days postcastration/sham.
BrdUrd incorporation experiments to trace the role of pro-
liferation in NE-differentiation were performed in a subset of
animals (five animals/time point). Male TRAMP mice were
implanted with minipumps (Alzet; Durect Corp., Cupertino,
CA) that contained 200 ml of BrdUrd (60 mg/ml; Sigma, St.
Louis, MO) at 12 weeks of age, and the minipumps were
maintained for 2 weeks to provide continuous BrdUrd re-
lease. Two days after pump removal, mice were castrated or
sham-castrated and tissue specimens were harvested at the
time points described above.
BrdUrd incorporation experiments to identify persistent
label-retaining cells were performed in TRAMP mice that
were 14 weeks old at the time of castration (n = 6 castra-
tion; n = 6 sham castration). Male TRAMP were castrated
or sham-castrated, implanted with BrdUrd minipumps (as
described above), and maintained for 2 weeks. The pumps
were removed and the animals were maintained for a
chase in the absence of BrdUrd for 4 weeks (42 days
postcastration/sham). Dorsal, lateral, and ventral prostates,
pelvic lymph nodes, small intestine, and any macroscopic
metastases were harvested at 20 weeks of age.
Tissues collected at necropsy from each animal were
fixed in 10% neutral-buffered formalin (Sigma) for 24 hours
in a single multichamber cassette, transferred to 70% etha-
nol, and embedded in a single paraffin block. Prostate lobes
were completely sectioned at 5-mm intervals and sections
were mounted on slides (ProbeOn-Plus; Fisher, Raleigh, NC).
Immunohistochemistry
Prostate and other tissues from TRAMP mice were pro-
cessed, and immunohistochemical (IHC) analyses per-
formed as described [32]. Briefly, slides were deparaffinized
in xylene, rehydrated through a graded series of alcohol
washes, and equilibrated in PBS. For Foxa1 and Foxa2 anti-
bodies, antigen retrieval was performed in 10 mM citric acid,
pH 6.0, for 30 minutes at 95jC in a steamer, or for antibodies
for AR, synaptophysin, Ki67, SV40-Tag, ABCG2, and seroto-
nin by continuous boiling in a microwave. Antigen retrieval for
the BrdUrd antibody was performed by incubating in 5 U/ml
DNase (Sigma) in Tris–boric acid–saline solution, pH 7.5, for
30 minutes at 37jC. Slides were incubated with appropriate
primary antibodies: 1:100 dilution of rabbit polyclonal anti-AR
(Calbiochem, San Diego, CA); 1:20 dilution of rat monoclonal
anti-ABCG2 (Bxp-53) (Caltag Laboratories, Burlingame, CA)
[33]; 1:600 dilution of rabbit polyclonal anti-synaptophysin
(Zymed Laboratories, South San Francisco, CA); 1:250 dilu-
tion of mouse monoclonal anti-BrdUrd (Sigma); 1:1000 dilu-
tion of rabbit polyclonal anti-Ki67 (Novocastra Laboratories,
New Castle, UK); 1:100 dilution of mouse monoclonal anti–
SV40-Tag (BD Pharmingen, San Diego, CA); 1:250 dilution of
rabbit polyclonal anti-serotonin (ICN, Immunobiologics, Irvine,
CA); 1:100 dilution of goat polyclonal anti-Foxa1 (Santa Cruz,
Santa Cruz, CA); 1:100 dilution of goat polyclonal anti-Foxa2
(Santa Cruz) for 30 minutes at 37jC. All slides were incubated
with the appropriate biotinylated secondary antibody: goat
anti–rabbit IgG (Vector, Burlingame, CA); rabbit anti–rat
IgG (Vector); goat anti–mouse IgG (Vector); or rabbit anti–
goat IgG (Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA) at a 1:1000 dilution for 20 minutes at 37jC. Im-
munoreactive antigens were detected using the Vectastain
Elite ABC Immunoperoxidase Kit and DAB, Nova Red (Vec-
tor), TrueBlue (KPL, Gaithersburg, MD), or ABC Alkaline
Phosphatase Kit I or III (Vector). Omission of primary antibody,
and tissue from animals not injected with BrdUrd (for BrdUrd
staining), served as negative controls, and positive control
tissues (small intestine for BrdUrd, Ki67, synaptophysin, and
ABCG2 staining, and prostate from intact TRAMP mouse for
SV40 and AR staining) were included for each experiment.
Quantitative and Statistical Analysis
The percent of cells that demonstrated SV40-Tag expres-
sion, proliferation, apoptosis, and BrdUrd incorporation was
determined by counting the number of epithelial cells that
stained positive for SV40-Tag, Ki67, activated caspase-3, or
BrdUrd, and the total number of epithelial cells detected by
morphology, in two to three representative 100 fields from
five animals/time point for tissue from the dorsal, lateral, and
ventral prostate lobes (average of 1000 epithelial cells/lobe).
Blood vessels were identified by staining endothelial cells
with CD31 and ABCG2, as described [14,32] in two to three
representative 100 fields from five animals/time point. Blood
vessels were counted and the perimeters weremeasured with
ImageJ software (NIH, Bethesda, MD) [34]. Means, standard
error, and one-way nonparametric ANOVA tests were per-
formed using Prism software (GraphPad, San Diego, CA).
Results
Expression of SV40-Tag Transgene in Prostate
of Castrated TRAMP Mice
SV40-Tag expression was evaluated in the three prostate
lobes (dorsal, lateral, and ventral) to determine changes in
epithelial SV40-Tag expression in response to castration.
The SV40-Tag index (Figure 1) was calculated in prostate tis-
sue specimens (benign prostate, prostatic intraductal neo-
plasia (PIN), and well-differentiated adenocarcinoma were
analyzed together, whereas poorly differentiated tumorswere
analyzed separately, and are discussed below). SV40-Tag
protein was expressed in 90% of the epithelial cells in the
dorsal, lateral, and ventral lobes of the prostate before cas-
tration, and expression was maintained at comparable levels
in sham castration (control) TRAMP mice. In castrated mice,
the percent of epithelial cells that expressed SV40-Tag was
decreased significantly in all lobes of the prostate on Day 2
postcastration, compared to prostates from sham-castrated
animals (P < .005), and continued to decrease over the
ensuing interval following castration (Figure 1, A–G).
SV40-Tag was expressed in less than 1% of epithelial cells
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in all lobes on Day 14 postcastration and, in the ventral
prostate, was observed only in focal areas or in poorly dif-
ferentiated tumors.
Proliferation and Apoptotic Indices of Prostate Epithelial
Cells following Castration
Expressions of Ki67, a marker of proliferation, and of
activated caspase-3, a marker of apoptosis, were evaluated
to determine the proliferative and apoptotic response to cas-
tration in epithelial cells in the three prostate lobes. The pro-
liferation and apoptotic indices were quantitated in prostate
tissues (normal, PIN, and well-differentiated adenocarci-
noma were analyzed together, whereas poorly differentiated
tumors were analyzed separately, and are discussed be-
low). The proliferation index in the dorsal and lateral lobes
was decreased significantly (2-fold) at Day 2 postcastration
compared to prostates from control animals (P < .05) (Fig-
ure 2A). Furthermore, the proliferation index in the ventral
lobe was decreased by more than 7-fold at Day 2 postcas-
tration compared to prostates from control mice (P < .05).
The proliferation index for all three lobes was reduced to
less than 1.5% of levels in sham castration mice on Day 14 of
postcastration.
Expression of activated caspase-3 increased in the pros-
tate between Days 1 and 4 postcastration (Figure 2B). The
apoptotic index increased 4-fold in the dorsal and lateral
lobes (P < .01) and increased 5-fold in the ventral lobe (P <
.005) on Day 1 postcastration compared to the corre-
sponding prostate lobes from control mice (Figure 2B). The
apoptotic index increased 2-fold in the dorsal and lateral
lobes (P < .01) on Days 2 and 4 postcastration compared to
Figure 1. Epithelial cell expression of SV40-Tag in TRAMP prostates
following castration (Cx). Dorsal prostate Day 1 postcastration (A) and Day 4
postcastration (B); Lateral prostate Day 1 postcastration (C) and Day 4 post-
castration (D); Ventral prostate Day 1 postcastration (E) and Day 4 post-
castration (F) immunostained for SV40-Tag. (G) The percent of epithelial
cells expressing SV40-Tag in each lobe of the prostate n dorsal, 5 lateral,
and & ventral. ***P < .001: Days 4, 7, and 14 postcastration compared to
sham-castrated animals in all lobes and Day 2 postcastration in the dorsal
lobe only. *P < .05: Day 2 postcastration compared to sham castration in the
lateral lobe. Black arrows, SV40-Tag–expressing cells Day 4 postcastration.
Scale bar, 20 m.
Figure 2. Epithelial cell proliferation and apoptosis in TRAMP prostates
following castration. (A) The percent of proliferation in epithelial cells in each
lobe of the prostate n dorsal, 5 lateral, and & ventral. *P < .05: Days 4, 7,
and 14 postcastration compared to sham-castrated animals in all lobes and
Day 2 postcastration in the dorsal and ventral lobes only. (B) The percent
of apoptosis in epithelial cells in each lobe of the prostate n dorsal, 5 lat-
eral, and & ventral. ***P < .001: Day 1 postcastration compared to sham-
castrated animals in ventral lobe. **P < .01: Days 1 and 2 postcastration
compared to sham-castrated animals in dorsal and lateral lobes. *P < .05:
Day 4 postcastration compared to sham-castrated animals in dorsal and lat-
eral lobes.
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the prostate lobes from control mice (Figure 2B). The percent
of cells undergoing apoptosis at Day 7 postcastration had
returned to sham castration levels. The ventral lobe of the
prostate, which demonstrated the most dramatic change
(> 6-fold decrease) in proliferation index in response to cas-
tration on Day 2 through Day 14 postcastration compared to
the ventral lobes from control mice, also demonstrated the
greatest increase in apoptosis index after castration (Fig-
ure 2, A and B).
Vascular Changes in TRAMP Prostate following Castration
The response of the prostatic vasculature to castration
was characterized by quantifying the number of blood ves-
sels per microscope field in prostate tissues characterized as
normal epithelium, PIN, and well-differentiated adenocarci-
noma (Table 1). Vascular changes in the large poorly differ-
entiated tumors were analyzed separately; they are discussed
in a later section. The perimeters of the blood vessels were
traced in the same fields used for quantification, the total
length of the perimeters of the blood vessel per field was
determined, and the average perimeter per vessel was cal-
culated for each time point postcastration (Table 1). No sig-
nificant differences in blood vessel density or average vessel
perimeter were observed between the three prostate lobes at
any time point (data not shown), therefore, the reported values
represent an average of the three lobes. There was a signif-
icant increase in the density of blood vessels on Day 14 post-
castration compared to the blood vessel density in prostates
from control mice (P < .05) (Table 1). However, there was
no significant difference in the perimeter of the blood vessels
between castrated and sham-castrated TRAMP animals
across the postcastration time points (Table 1). The increased
number of blood vessels in Day 14 postcastration without an
increase in total vessel perimeter suggests that the new blood
vessels are smaller postcastration, and possibly are the result
of active angiogenesis.
BrdUrd Retention Used to Examine Proliferation/
Differentiation following Castration
In the initial series of BrdUrd label-retention experiments,
TRAMP mice were implanted with BrdUrd-filled osmotic
pumps at 12 weeks of age, the pumps removed following 2
weeks of continuous BrdUrd infusion and, 2 days following
pump removal, mice were castrated or sham-castrated.
Long-term retention of BrdUrd was used to track the dynam-
ics of prostate cell populations following castration. The cen-
tral goal of the studywas to determine whether the emergence
of synaptophysin-expressing cells that comprised the poorly
differentiated tumors was the result of differentiation of the
progeny of a prostate label–retaining cell, requiring multiple
cell divisions during progression through the transit-amplifying
compartment, or was the result of transdifferentiation from an
adenocarcinoma cell, without cell division. BrdUrd label was
present in almost all epithelial cells of the highly proliferative
small intestine used as a positive control at the time of cas-
tration (Day 0, data not shown). However, BrdUrd label was
diluted from intestinal epithelial cell nuclei by the rapid prolif-
eration that occurred over the days that followed removal of
the osmotic pump (data not shown). The percentage of intes-
tinal epithelial cells that retained BrdUrd label was related
inversely to the rate of proliferation of the cells that had in-
corporated BrdUrd during the pulse period. In contrast, only
5% to 9% of adenocarcinoma cells in the prostates of TRAMP
mice demonstrated BrdUrd incorporation at the time of cas-
tration (Figure 3), suggesting a relatively low rate of prolifer-
ation. At Day 14 postcastration, BrdUrd label was retained in
2-fold more tumor cells in the lateral and ventral prostates
compared to sham-castrated control mice (Figure 3) reflecting
the reduced rate of proliferation in the absence of circulating
androgens. In contrast, in the poorly differentiated tumors that
emerge after castration, < 0.2% of cells retained label after
the 16-day chase, reflecting the high rate of proliferation in
these cells.
Table 1. Changes in TRAMP Prostate Vasculature following Castration.
No. of Days
Postcastration
Blood Vessel Density
(No./Field)
Blood Vessel Perimeter
(mm/Field)
0 13.03 ± 1.35 74.09 ± 5.31
1 10.47 ± 0.92 89.44 ± 7.07
2 13.58 ± 1.82 72.86 ± 6.72
4 13.52 ± 0.89 69.82 ± 2.74
7 14.37 ± 1.00 72.09 ± 4.35
14 18.16* ± 2.054 68.07 ± 3.83
*P < .05 compared to sham-castrated TRAMP mice.
Figure 3. BrdUrd retention in epithelial cells in TRAMP prostates following
castration n dorsal, 5 lateral, and & ventral lobes of the prostate from
animals sham-castrated (A) or castrated (B).
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There was no evidence of synaptophysin-expressing,
BrdUrd-positive cells in either intact or castrated animals.
This observation suggested that synaptophysin-expressing
cells were the result of proliferation and differentiation of
progeny of a progenitor cell and not transdifferentiation
of an adenocarcinoma cell. Therefore, the incidence of
synaptophysin-expressing cells (single cell or foci of cells)
in the ventral prostate per slide was determined (Table 2).
Synaptophysin-expressing cells located within the basement
membrane of the glands (intraglandular) were quantitated
as two separate categories: foci of one to two cells that
expressed synaptophysin (Figure 4A) or foci of more than
two cells that expressed synaptophysin (Figure 4, B and C).
Synaptophysin-expressing/BrdUrd-negative cells present on
Day 1 postcastration, after 3 days of chase (BrdUrd removal),
were observed at the same frequency in intact and castrate
animals, supporting that the synaptophysin-expressing cells
were highly proliferative in both intact and castrated animals
(Figures 5A and 6A), or were present at the time of castration
but were not proliferative during the pulse period (Figure 4, A
and B). However, rare synaptophysin-expressing foci associ-
ated with BrdUrd-retaining cells on the periphery of the foci
suggest that the synaptophysin-expressing foci derive from
label-retaining cells (Figure 4C).
Synaptophysin-Expressing Foci and Tumors in TRAMP
Ventral Prostates
Synaptophysin-expressing cells were associated with
three pathologies in the ventral prostate of both intact and
castrated TRAMPmice (Figures 5 and 6): foci localized within
glands (intraglandular foci) (A); microscopic tumors, invasive
tumor that was not visible grossly on dissection (B); and mac-
roscopic tumors, visible on dissection (C). Serial sections con-
taining these synaptophysin-expressing foci/tumors were
examined by IHC for coexpression of: SV40-Tag (Figures 5,
D–F and 6, D–F ); AR and ABCG2, a putative progenitor
cell marker (Figures 5, G– I and 6, G– I); Foxa2, a transit-
amplifying cell marker (Figures 5, J–L and 6, J–L); serotonin,
a NE cell marker (Figure W1, A–C); and Foxa1, an epithelial
cell marker (Figure W1, D–F). Metastases in pelvic lymph
nodes from the same mice (when present) are shown in the
insets. In general, all synaptophysin-expressing, poorly dif-
ferentiated foci and tumors coexpressed SV40-Tag, Foxa1,
and Foxa2 and had high levels of proliferation as detected
with Ki67. Rare intraglandular foci (1/24), microscopic tumors
(1/14), and macroscopic tumors (2/19) that expressed syn-
aptophysin, but not Foxa2, were detected, in both intact and
castrated animals (Table 2). AR expression was detected in a
few synaptophysin-expressing foci and tumors from intact and
castrated animals, and AR expression was usually correlated
with a lack of Foxa2 expression (Table 2). AR expression was
detected in a single lymph node metastasis (Figure 5G, inset)
in an intact animal; the lymph node metastasis coexpressed
synaptophysin and SV40-Tag (Figure 5, A and D), but not
Foxa2 (Figure 5J ). This metastasis possibly represents a rare
instance of AR, not Foxa2 driving the probasin promoter in a
synaptophysin-expressing metastatic tumor.
Prostates from castrated TRAMP demonstrated AR ex-
pression in the cytoplasm of adenocarcinoma cells on Days 1
and 4 postcastration (Figure 6G), but AR expression was
nuclear beginning at Day 7 postcastration (data not shown),
and AR expression remained nuclear at Day 14 postcastra-
tion (Figure 6H ). The percent of luminal epithelial cells that
expressed SV40-Tag decreased after castration, until SV40-
Tag expression was not detectable on Day 14 postcastration,
even in epithelial cells that had regained nuclear AR expres-
sion (Figure 6, E and H ). Synaptophysin-expressing cells in
foci, or in tumors, were the only cells in castrate prostates
that expressed SV40-Tag and Ki67 on Day 7 and Day 14
following castration (Figure 6, B and E ). Serotonin coexpres-
sion with synaptophysin was observed inf 27% of the intra-
glandular foci following castration (Figure W1G; Table 2), and
was also observed in 15% of intraglandular synaptophysin-
expressing foci from intact TRAMP; however, coexpression
of serotonin was never detected in microscopic or macro-
scopic tumors (Figure W1, E–F and H– I ). Foxa1 was ex-
pressed in synaptophysin-expressing foci and tumors, but
was expressed intensely in synaptophysin-negative cells
(FigureW1, J–L). The coexpression of synaptophysin, Foxa2,
SV40-Tag, and Ki67 in the intraglandular foci, microscopic
Table 2. Incidence of Synaptophysin- or Foxa2-Expressing Cells in TRAMP Prostates.
No Foci Intraglandular Synaptophysin
or Foxa2+, 1–2 Isolated Cells
Intraglandular Synaptophysin
or Foxa2+, > 2 Cells (Foci)
Microscopic Tumor Macroscopic Tumor
Intact Cx Intact Cx Intact Cx Intact Cx Intact Cx
No. of animals 17 19 5 4 6 10 11 7 3 11
Frequency of
Synaptophysin+
or Foxa2+/Slide
26/65 (0.4) 33/82 (0.4) 8/65 (0.12) 9/82 (0.08) 18/65 (0.28) 16/82 (0.2) 14/65 (0.22) 9/82 (0.11) 5/65 (0.08) 17/82 (0.21)
No. of LN
Metastasis/
Animal/+/NA
8/1/8 9/1/9 2/0/3 1/0/3 5/1/0 7/1/2 3/0/8 4/0/3 0/3/0 3/4/4
Frequency of
Serotonin+/Foci
NA NA Not found on serial slides 2/13 3/11 0 0 0 0
Frequency of
Foxa2/Foci
NA NA Not found on serial slides 1/13 0 0 1/6 1/4 1/15
AR+/Foci NA NA Not found on serial slides 3/13 0 4/8 1/6 2/4 1/15
There is a significant difference in the number of animals with different pathologies between intact and castrated (Cx) TRAMP in these defined categories with P <
.05, chi-square analysis. The frequency of serotonin+, Foxa2, and AR+ is per synaptophysin-expressing foci.
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tumors, and macroscopic tumors from intact and castrated
TRAMP mice suggest an index phenotype for the emerging
poorly differentiated tumors unique from the adenocarci-
nomas, particularly in the castrate prostate.
The incidence of intraglandular, isolated synaptophysin-
expressing cells and of foci of synaptophysin-expressing cells,
microscopic tumors, and macroscopic tumors was calculated
for the ventral prostates from intact and castrated TRAMP
mice. All ventral prostates without macroscopic tumors were
sectioned completely, and sections spaced at 25-mM intervals
were examined by IHC analysis for the expression of Foxa2,
synaptophysin, and SV40-Tag (Table 2). A significant differ-
ence (chi-square analysis) was observed for the total num-
ber of foci and tumors between intact and castrated TRAMP
mice (P < .05). However, there was no statistical differ-
ence between intact and castrated animals when comparing
the individual types of foci or tumors. The proliferation and
apoptotic indices, the blood vessel density, and the length of
vessel perimeter per field were calculated in intraglandular
synaptophysin-expressing foci and in both microscopic and
macroscopic tumors (Table 3). There was no difference in
blood vessel density, length of vessel perimeter, and prolif-
eration or apoptotic indices between cells in the intraglandular
synaptophysin-expressing foci and tumors in sham-castrated
and in castrated TRAMP mice (Table 3). Based on marker
expression, the pattern of proliferation, and the expression
of synaptophysin following castration, the intraglandular foci
could represent the precursor to the microscopic and macro-
scopic tumors that arise rapidly after castration.
Metastasis
Pelvic lymph nodes were harvested and examined for
evidence of metastasis. The majority of pelvic lymph node
metastases were found in animals that had macroscopic
tumors. The metastatic cells expressed synaptophysin,
SV40-Tag, and Foxa2 and lacked detectable levels of AR.
However, metastases were observed in both intact and cas-
trated animals that lacked synaptophysin, and a single
metastasis that expressed synaptophysin, SV40-Tag, and
detectable AR, but not Foxa2, was detected in an intact an-
imal that had an intraglandular synaptophysin-expressing
foci, but no microscopic or macroscopic tumors within the
ventral prostate (Figure 5, A, D, G, and J ).
Label-Retaining Cells following Castration
A second BrdUrd-based experimental format was em-
ployed to examine the origin of synaptophysin-expressing
cells that become apparent after castration. TRAMP mice
were implanted with osmotic pumps containing BrdUrd and
were either castrated or sham-castrated. The pumps were
removed following 2 weeks of continuous BrdUrd labeling,
the animals were maintained for a 2-week chase period, and
tissues were harvested. Macroscopic tumors were present in
3/6 castrated mice (1/6 with positive pelvic lymph nodes) and
1/6 sham-castrated mice (1/6 with positive pelvic lymph
nodes). There was no detectable BrdUrd within the macro-
scopic tumors that expressed synaptophysin, Foxa1, Foxa2,
and SV40-Tag, and these tumors had weak-to-undetectable
levels of AR and did not express serotonin. In prostates
without macroscopic tumors, the entire ventral prostate was
paraffin-embedded and sectioned, and sections at 25-mm
intervals were stained for synaptophysin and Foxa2 to
identify intraglandular foci that expressed synaptophysin
and/or Foxa2. The five ventral prostates harvested from
intact animals that lacked macroscopic tumors contained
two separate intraglandular foci that expressed synaptophy-
sin and Foxa2 (2/5 prostates). In contrast, the three ventral
prostates from castrated animals that lacked macroscopic
tumors contained six independent intraglandular foci that
Figure 4. BrdUrd retention in synaptophysin-expressing intraglandular foci.
Ventral prostate Day 1 postcastration and Day 3 post –BrdUrd removal (A
and B); Day 4 postcastration and Day 6 post –BrdUrd removal (C);
immunostained for BrdUrd – blue and synaptophysin – red. BrdUrd label –
retaining cells (black arrows) and synaptophysin-expressing cells (green
arrows) postcastration. Scale bar, 20 m.
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expressed synaptophysin and Foxa2 foci (6/3 prostates).
Figure 7 (A–D) shows serial sections of a representative
intraglandular, synaptophysin- and Foxa2-expressing focus
that had BrdUrd label–retaining cells located on the pe-
riphery of the foci. All synaptophysin-expressing intraglandu-
lar foci and macroscopic tumors expressed Foxa1, Foxa2,
and SV40-Tag, but not AR. In cells that expressed AR,
but not synaptophysin or SV40-Tag, AR was consistently
nuclear in localization (Figure 7C ). All BrdUrd-labeled cells
(Figure 7A) represent cells that proliferated during the 14 days
postcastration, but were not proliferatively active during
the 14-day chase period. BrdUrd-positive cells were not
detected within synaptophysin-expressing foci, but were
frequently observed peripheral to the foci, suggesting that
synaptophysin-expressing foci derive from postcastration
label–retaining cells.
Figure 5. Synaptophysin-expressing intraglandular foci and tumors in ventral prostate from 14- to 16-week-old intact TRAMP mice. Intraglandular synaptophysin-
expressing foci (black arrow) with lymph node metastasis (inset) (A, D, G, and J); Microscopic tumor (black arrow) (B, E, H, and K); and Macroscopic tumor with
lymph node metastasis (inset) (C, F, I, and L) immunostained for synaptophysin – red and Ki67 – blue (A–C); SV40-Tag – brown (D–F); AR – red and ABCG2 –
blue (G– I); and Foxa2 – brown (J–L). Arrows indicate synaptophysin-, SV40-Tag– , and Foxa2-expressing intraglandular foci. Arrowheads indicate synaptophysin-
and Foxa2-negative cells. Scale bar, 20 m.
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Discussion
The effects of castration on multiple cellular compartments,
the luminal and tumor epithelial cells and endothelial cells, of
the TRAMP prostate were characterized to identify changes
that occur in castrate prostates that may serve as a model
of mechanisms that support the emergence of castration-
recurrent prostate cancer in humans. In previous studies in
the rodent prostate, the apoptotic death of secretory/luminal
epithelial cells, 3 to 5 days following androgen ablation, were
suggested to be a consequence of changes in the prostate
stroma or in the prostate vasculature [35–37]. In TRAMP, we
observed increased epithelial cell apoptosis between Days 1
and 4 postcastration; however, there was no decrease in
blood vessel density or perimeter during this interval. In ad-
dition, SV40-Tag–expressing luminal epithelial cells in PIN
lesions and well-differentiated adenocarcinomas in TRAMP
Figure 6. Synaptophysin-expressing intraglandular foci and tumors in ventral prostate from castrated TRAMP mice. Intraglandular synaptophysin-expressing foci
Day 4 postcastration (black arrow) (A, D, G, and J); Microscopic tumor Day 14 postcastration, black arrow; synaptophysin-expressing intraglandular foci (B, E, H,
and K); and Macroscopic tumor Day 7 postcastration with lymph node metastasis (inset) (C, F, I, and L) immunostained for synaptophysin – red and Ki67 – blue
(A–C); SV40-Tag – brown (D–F); AR – red and ABCG2 – blue (G– I); and Foxa2 – brown (J–L). Arrows indicate synaptophysin-, SV40-Tag– , and Foxa2-
expressing intraglandular foci. Arrowheads indicate synaptophysin- and Foxa2-negative areas. Scale bar, 20 m.
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lose SV40-Tag expression almost completely by Day 7
postcastration, indicating that transgene expression was
regulated by androgens in both differentiated luminal cells
and adenocarcinoma cells, consistent with previous reports
[38]. Involution of TRAMP prostate epithelial cells occurred
more rapidly than reported previously in nontransgenic rodent
prostates, with the difference possibly due either to the higher
number of epithelial cells in the TRAMP prostate or to the
rapid loss of expression of the AR-regulated SV40-Tag protein
that produces immortalization and expansion of the SV40-Tag
expressing cells into adenocarcinomas.
The selective emergence of intraglandular foci of poorly
differentiated cancers comprised of synaptophysin- and
Foxa2-expressing cells in the castrate animals could be
driven by Foxa2 transactivation of the probasin promoter of
the SV40-Tag in the androgen-deprived prostates [6]. Foxa2,
therefore, could substitute for the loss of AR-mediated tran-
scription of SV40-Tag in the emerging synaptophysin-
expressing foci. Foxa2 is required for the determination of
endoderm cell fate and is one of the earliest differentiation
markers expressed during endodermal development [39].
Furthermore, Foxa2 is expressed both in nascent prostate
buds during the early stages of organogenesis [40] and in
advanced stage prostate cancers, including small cell carci-
noma of the prostate [6]. Therefore, Foxa2 may mediate
expression of the SV40-Tag transgene in a malignantly
transformed progenitor cell, or transit-amplifying cell, deter-
mining the expansion of synaptophysin-expressing foci into
macroscopic tumors and metastases in the absence of an-
drogen. Whereas SV40-Tag expression under the regulation
of Foxa2 in progenitor cells may drive emergence of poorly
differentiated (NE-like) cancers, SV40-Tag expression under
the regulation of AR in secretory epithelial cells does not
drive progression of androgen-stimulated adenocarcinomas
to castration-recurrent, poorly differentiated prostate can-
cers, further suggesting that poorly differentiated tumors and
adenocarcinomas have different origins. The emergence of
these poorly differentiated foci, therefore, may provide a valu-
able model for the analysis of the role in recurrence of modu-
lation of the prostatemicroenvironment by androgen-deprivation.
AR versus Foxa2 regulation of the minimal probasin
promoter determines the response of the SV40-Tag express-
ing cell to castration. The benign luminal epithelial cells and
adenocarcinoma cells depend on androgen for SV40-Tag
expression, and immortalization/tumorigenicity is lost when
androgen stimulation is ablated by castration. The loss of
SV40-Tag expression in the AR-expressing adenocarcinoma
cells in response to castration was associated with de-
creased proliferation and increased apoptosis. Furthermore,
luminal epithelial cells that survived castration and regained
AR nuclear expression by Day 14 postcastration did not
regain expression of SV40-Tag. In contrast, Foxa2- and
synaptophysin-expressing cells did not respond to castration;
they maintained SV40-Tag expression and demonstrated no
change in proliferation or apoptosis. In fact, it is possible that
the AR- and SV40-Tag–expressing well-differentiated ade-
nocarcinoma cells suppress progression of synaptophysin-
expressing foci in intact TRAMP, and castration-induced
regression of the androgen-stimulated adenocarcinoma cells
allows the progression of the synaptophysin-expressing foci.
The change in regulation of SV40-Tag expression from AR
to Foxa2 may drive expansion of the NE-like, poorly differen-
tiated cancers in the androgen-deprived environment.
BrdUrd label–retaining experiments were designed to
differentiate the three possible origins for the synaptophysin-
expressing foci of poorly differentiated cancers that pro-
gressed rapidly in the androgen-deprived environment of the
castrate prostate. A BrdUrd pulse for 2 weeks in intact animals
labeled proliferating tumor cells and facilitated testing the
hypothesis that foci of poorly differentiated tumors resulted
from transdifferentiation of an adenocarcinoma cell into a NE
cell in response to castration, without requiring proliferative
intermediates. The postmitotic NE cell would express NE
markers and retain BrdUrd through the chase period following
castration. Alternatively, tumor cells in foci that expressed NE
markers could represent the progeny of a label-retaining cell.
The slowly self-renewing cancer stem cell presumably would
retain BrdUrd; however, their progeny would dilute rapidly the
incorporated BrdUrd label on entering the transit-amplifying
compartment which may or may not express NE markers,
before initiating expression of the differentiation-associated
NE markers. In TRAMP, BrdUrd label was not detected in
isolated synaptophysin-expressing cells on Day 1 or 2 post-
castration, therefore, it does not appear that transdifferentia-
tion occurred immediately postcastration in the TRAMP
model, as was observed in the PC-295 and PC-310 human
prostate cancer xenografts [26,27,41]. Furthermore, the highly
proliferative intraglandular synaptophysin-expressing foci
were detected at a similar frequency in sham-castrated mice
and in castrated mice, suggesting that the foci were present
before castration. Our studies support the hypothesis that
transactivation of SV40-Tag by Foxa2 in a tumor progenitor
cell drives expansion of the poorly differentiated foci in the
absence of androgen and suggest that changes in the en-
vironment of these cells determine the probability and kinet-
ics of their progression to macroscopic tumors.
Table 3. Comparison of Blood Vessel Density, Proliferation, and Apoptosis between Intraglandular Synaptophysin-Expressing Foci and Microscopic or
Macroscopic TRAMP Prostate Tumors.
Intraglandular Synaptophysin+ Foci Micro- or Macroscopic Tumors
Intact Cx Intact Cx
Blood Vessel Density NA NA 8.27 ± 1.05 6.133 ± 0.84
Blood Vessel Perimeter (mm/Field) NA NA 153.80 ± 38.9 113.42 ± 10.3
Proliferation Index (%) 50.7 ± 17.7 64.8 ± 16.6 77.6 ± 12.3 88.6 ± 8.9
Apoptosis Index (%) 0.48 ± 0.4 0.1 ± 0.05 1.3 ± 0.4 1.2 ± 0.4
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A tumor stem cell model for the etiology and progression
of prostate cancer is consistent with the predictable emer-
gence of these foci of poorly differentiated cancer in TRAMP
and castration-recurrent prostate cancer in humans. In a tu-
mor stem cell–driven model of cancer, a small population of
tumor stem cells escapes tissue microenvironmental con-
straints on self-renewal, as well as therapeutic regimens
including androgen-deprivation therapy, and gives rise to
progeny that abnormally/incompletely/aberrantly differenti-
ate (express synaptophysin) in response to the presence/
absence of microenvironmental signals. The tendency of
prostate cells to acquire NE characteristics on androgen-
deprivation may indicate that differentiation toward a NE lin-
eage represents a default survival mechanism of prostate
stem cell progeny. Potential markers for prostate stem cells
and/or prostate tumor stem cells are currently being inves-
tigated by several groups. Xin et al. [42] have proposed that
Sca-1 expression marks the prostate-regenerating cell in the
mouse. Sca-1–expressing prostate-regenerating cells rep-
resented approximately 30% of cells in proximal regions of
prostate tubules and 10% of cells in the distal tips, and the
relative percent of Sca-1+ cells increased to 70% after cas-
tration [42]. Furthermore, Sca-1–expressing cells regener-
ated whole tubular structures in tissue recombination studies
with rat urogenital mesenchyme [42]. Schalken and van
Leenders [43] have proposed that prostate stem cells can
be identified by expression of intermediate patterns of cyto-
keratins that reflect all of the potential differentiated progeny
of the stem cell. The least differentiated stem cells are pro-
posed to express cytokeratin 5 and cytokeratin 14, with weak
expression of cytokeratin 18 [43]. Intermediate stages of dif-
ferentiation by the progeny of the stem cells that have exited
the stem cell compartment are indicated by expression of
cytokeratin 5, cytokeratin 18, c-met, a2-integrin, and induc-
ible laminin-g2 [43]. Malignant transformation of an interme-
diate cell would explain how prostate cancer cells express
markers of both secretory (cytokeratin) and neuroendocrine
(chromogranin A) differentiation. Finally, several groups of
investigators have proposed that the prostate stem cell is
typified by coexpression of a group of markers, CD44+/a2b1
hi/
CD133+ [44,45]. These markers identify approximately 0.1%
of epithelial cells in benign prostate and prostate cancer, and
only CD133+ cells isolated from tumors were capable of self-
renewal and extensive proliferation [45]. The CD44+/a2b1
hi/
CD133+ cell population, when engrafted with human prostate
stromal cells, gave rise to cytokeratin 8/prostatic acid phos-
phatase/AR-expressing xenografts; loss of CD133 may indi-
cate relocation to the transit-amplifying compartment and
loss of the stem cell phenotype [44]. We reported recently
that the prostate stem cell and prostate tumor stem cell in
mouse, rat, and humans was characterized by expression of
the ATP-binding cassette transporter family membrane efflux
pump ABCG2 (BCRP) and by lack of AR protein [32]. Cells
that coexpressed ABCG2 and the SV40-Tag transgene were
not observed in prostates from TRAMP mice. The lack of
expression of SV40-Tag in the putative stem cell could be
due to the lack of expression of AR or Foxa2 in the ABCG2-
expressing cells. Expression of AR in stem cell progeny
could be correlated with commitment to differentiation along
a luminal epithelial lineage, whereas expression of Foxa2 in
stem cell progeny could be correlated with commitment to
NE differentiation.
This study suggests that the majority of the macroscopic,
poorly differentiated tumors that represent the lethal pheno-
type in TRAMP are independent of, and not a progression
Figure 7. BrdUrd label – retaining cells following castration. BrdUrd implanted
at the time of castration at 14 weeks of age and BrdUrd was removed at 16
weeks of age, serial prostate sections were immunostained following 5 weeks
of castration and 3 weeks of BrdUrd removal for BrdUrd – blue and
synaptophysin – red (A); SV40-Tag – brown (B); AR – red and ABCG2 –
blue (C); or Foxa2 – brown (D). Black arrows indicate BrdUrd label – retaining
cells. Green arrows indicate synaptophysin-expressing cells postcastration.
Scale bar, 20 m.
948 Origin of Poorly-Differentiated Prostate Tumors in TRAMP Huss et al.
Neoplasia . Vol. 9, No. 11, 2007
from, the PIN and well-differentiated adenocarcinomas that
are a result of AR-mediated, SV40-Tag transgene expression
in secretory epithelial cells. The rare, poorly differentiated,
primary and metastatic tumors that express synaptophysin
support an origin from a transformed transit-amplifying cell
committed to a NE lineage, with SV40-Tag driving the tumor-
igenic phenotype under the regulation of Foxa2 upregulated
in the absence of AR [4]. The potential of TRAMP to model a
transformed transit-amplifying and or intermediate cell re-
sulting in androgen-insensitive prostate cancer would pro-
vide a valuable tool for the identification and characterization
of the prostate cancer stem cell and lead to a preclinical tool
for testing therapies designed to target the prostate cancer
stem cell.
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Figure W1. Serial sections from Figures 5 and 6 of intraglandular foci, microscopic, and macroscopic tumors from intact TRAMP mice (A–F) and castrated TRAMP
mice (G–L). Serial sections were immunostained for serotonin (A–C; G– I) or Foxa1 (D–F; J–L). Arrows indicate synaptophysin-, SV40-Tag– , and Foxa2-
expressing intraglandular foci. Arrowheads indicate synaptophysin- and Foxa2-negative areas. Green arrow indicates serotonin-expressing cell. Scale bar, 20 m.
